Scientific instruments maker PerkinElmer Inc said on Monday it would buy Germany’s Euroimmun Medical Laboratory Diagnostics AG for about $1.3 billion in cash to expand its reach into autoimmune and allergy diagnostic markets.
The deal also offers new infectious disease capabilities to its customers in China, PerkinElmer said.
The acquisition is expected to add about $0.28 to $0.30 per share to PerkinElmer’s 2018 adjusted earnings, it said, and reaffirmed its 2017 revenue and earnings per share forecast.
Lubeck, Germany-based Euroimmun, which has about 2,400 employees, is expected to generate about $310 million in revenue this year, PerkinElmer said in a statement.
The deal is expected to close in the fourth quarter of 2017, PerkinElmer said.
By Subrat Patnaik
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.